Application and development of molecular diagnostic techniques for detection infectious diseases / 中华检验医学杂志

With the development of the concept of precision medicine, under the background of the new coronavirus pneumonia epidemic, the clinical diagnosis and treatment of infectious diseases has received more and more attention. The experimental diagnosis technology with molecular biology as the core is used as important means for the clinical laboratory diagnosis of infectious diseases. This lcind of technology is paid special attention. In recent years, advances in nanomaterials, applied chemistry, photophysics, and biosensing technologies have also ushered in revolutionary and creative developments in molecular diagnostic technology. This article reviews the application and development of the latest molecular diagnostic technologies, such as next-generation quantitative PCR technology and gene sequencing technology, isothermal amplification technology, biochip and biosensor technology in the clinical diagnosis of infectious diseases.

The Emerging Focus on Pharmacogenomics

Drugs are designed to treat medical conditions for the general population. Idiosyncratic reactions to drugs are determined by the individual’s respective genetic variations that direct effectiveness and side effects. Adverse drug reactions rank within the top ten leading causes of death in the developed world. The field of pharmacogenomics has advanced in the last fifty years, picking up significant momentum with recent biotechnological developments that allowscientists to investigate the human genome and provide individualized drug therapy that will increase the efficacy of drugs and decrease the incidence of adverse drug reactions. Pharmacogenomics has reached a milestone in making personalized medicine accessible and effective. The medical community shares this responsibility for the emerging focus on pharmacogenomics with regulatory agencies and bioinformatics specialists as they struggle to streamline vast libraries of information and reconcile public and regulatory approval on this critical path to the next level of health care.

The application of chromosome abnormality chip detection in male infertility / Aplicación de la detección de la anormalidad del cromosoma mediante biochips genéticos en la infertilidad masculina

OBJECTIVE: To discuss the application of microarray technology in the diagnosis of male infertility. METHODS: Sixteen loci, including a sex-determining region on the Y chromosome, were investigated by polymerase chain reaction (PCR) in infertile male patients. Chromosome abnormality chip with 180 000 probes was used to detect small deletion, small amplification and loss of heterozygosity. RESULTS: By PCR, nine of 103 infertile patients were found to have sequence-tagged site microdeletions. Microdeletions were not observed in control samples. The deletions detected by PCR were present in six azoospermic men (6/44, 13.6%) and in three oligoasthenoteratozoospermic (OATS) men (3/59, 5%). The overall frequency of microdeletions in infertile men was 8.7% (9/103). Chromosome abnormality chip detection 500+ detected more amplification or deletion in 51 infertile patients and the overall frequency of microdeletions in infertile men was 49.5% (51/103). CONCLUSION: Chromosome abnormality chip detection system provides a sensitive, economic and high-throughput method for detecting the deletion or amplification of genomic DNA sequences of infertile patients. Not only can it identify Yq deletions, but it can also find other chromosome abnormalities and facilitate the understanding of male infertility.

OBJETIVO: Analizar la aplicación de la tecnología de los microarreglos en el diagnóstico de la infertilidad masculina. MÉTODOS: Dieciséis loci, incluyendo una región determinante del sexo en el cromosoma Y, fueron investigados mediante reacción en cadena de la polimerasa (RCP) en pacientes hombres con problemas de infertilidad. Un biochip de la anormalidad cromosómica, con 180000 sondas, fue utilizado a fin de detectar pequeñas delecciones, pequeñas amplificaciones y pérdidas de heterocigosidad. RESULTADOS: Por medio de la RCP, se halló que nueve de 103 pacientes con infertilidad presentaban microdelecciones de sitios de secuencia marcada. Las microdelecciones no fueron observadas en las muestras de control. Las delecciones detectadas mediante RCP, estuvieron presentes en seis hombres azoospérmicos (6/44, 13.6%) y en tres hombres con oligoastenoteratozoospermia (OAT) (3/59, 5%). La frecuencia general de las microdelecciones en los hombres infértiles fue 8.7% (9/103). La detección con biochip de la anormalidad cromosómica de 500+ detectó más amplificación y delección en 51 pacientes, y la frecuencia general de microdelecciones en los hombres infértiles fue 49.5% (51/103). CONCLUSIÓN: El sistema de detección de la anormalidad del cromosoma mediante biochips genéticos representa un método sensible, económico, y de alto rendimiento, para detectar la delección o amplificación de las secuencias genómicas de ADN de pacientes infértiles. Este método puede no sólo identificar las delecciones Yq, sino también hallar otras anormalidades cromosómicas, facilitando así la comprensión de la infertilidad en los hombres.

Differences in pharmacological pathways among Qingkailing effective component / 中国药理学通报

AimPurpose-The aim of this study is utilizing the highthrough genechip data to Compare the difference of the pharmacological pathways among the Qingkailing effective components Baicalin(BA),Jasminoidin(JA),cholic acid(CA) and Concha margaritiferausta(CM)in the treatment process of cerebral ischemia.Methods The focal cerebral ischemia-reperfusion model mice were randomly divided into groups of Baicalin(BA),Jasminoidin(JA),cholic acid(CA),Concha margaritiferausta(CM)and model group(M),15 mice for each group,24 hours later total RNA were abstracted from the hippocampus,we selected 374 gene expression profile related to cerebral ischemia,made cDNA chip marked by Cy3/Cy5,detect the variation of different components,Then apply Arraytrack software to select differentiate expressed genes between BA and M,JA and M,CA and M,CM and M by T-tests,select genes with P<0.05,Fold change>1.5,according GeneGO software to find the top two pathways of each components.Results the number of differentiate expressed genes between BA,JA,CA,CM and M is separately 46,50,54 and 30,according to the top two pathways of GeneGo display JA,CA,CM all participate Apoptosis and survival_TNFR1 signaling pathway,besides BA participate in regulating G-protein signaling and Development_A2A receptor signaling while CA in Neurophysiological process_NMDA-dependent postsynaptic long-term potentiation in CA1 hippocampal.Conclusion Qingkailing effective components take diversity Pharmacological characteristics,BA mainly for anti-apoptosis,JA mainly for inhibit apoptosis and promote ischemic brain protection,etc,CA focused on inhibiting calcium influx,and anti-neuron variability.But CM has no good results on this.

Bacterial handling under the influence of non-uniform electric fields: dielectrophoretic and electrohydrodynamic effects

This paper describes the modeling and experimental verification of a castellated microelectrode array intended tohandle biocells, based on common dielectrophoresis. The proposed microsystem was developed employing platinumelectrodes deposited by lift-off, silicon micromachining, and photoresin patterning techniques. Having fabricated the microdevice it was tested employing Escherichia coli as bioparticle model. Positive dielectrophoresis could be verified with the selected cells for frequencies above 100 kHz, and electrohydrodynamic effects were observed as the dominant phenomena when working at lower frequencies. As a result, negative dielectrophoresis could not be observed because its occurrence overlaps with electrohydrodynamic effects; i.e. the viscous drag force acting on the particles is greater than the dielectrophoretic force at frequencies where negative dielectrophoresis should occur. The experiments illustrate the convenience of this kind of microdevices to micro handling biological objects, opening the possibility for using these microarrays with other bioparticles. Additionally, liquid motion as a result of electrohydrodynamic effects must be taken into account when designing bioparticle micromanipulators, and could be used as mechanism to clean the electrode surfaces, that is one of the most important problems related to this kind of devices.

Este artigo descreve a modelagem e teste experimental de uma rede de microeletrodos em cremalheira cujo objetivo é o manuseio de células biológicas, com base em dieletroforese comum. O microsistema proposto foi desenvolvido empregando eletrodos de platina depositados por técnicas de 'lift-off', micro-usinagem em silício e litografia com foto-resina. Uma vez fabricado o microdispositivo, este foi testado utilizando a Escherichia coli como modelo de biopartículas. Dieletroforese positiva pode ser observada com as células selecionadas para freqüências acima de 100kHz, e efeitos eletro-hidrodinâmicos foram observados como o fenômeno dominante para menores freqüências. Como resultado, a dieletroforese negativa não pode ser observada pois sua ocorrência se sobrepõe a efeitos eletro-hidrodinâmicos; i.e. a força de arraste viscoso atuando sobre as partículas é superior à força dieletroforética para freqüências em que a dieletroforese negativa deveria ocorrer. Os experimentos ilustram a conveniência deste tipo de micro-dispositivo para o micromanuseio de objetos biológicos, abrindo a possibilidade de uso destas micro-redes com outras partículas biológicas. Além disto, o movimento líquido como resultado dos efeitos eletro-hidrodinâmicos deve ser levado em conta ao se desenhar micromanipuladores de partículas biológicas, e pode ser utilizado como mecanismo para limpar as superfícies dos eletrodos, que é um dos problemas mais importantes relacionados a este tipo de dispositivo.

The Present and Future of Nanotechnology in Medicine / 대한간학회지

No abstract available.

Application of multi-tumor markers protein chip diagnose system in the diagnosing of ovarian cancer / 中华检验医学杂志

Objective To investigate the application of Multi-tumor markers Protein Chip Diagnose System in the diagnosing of ovarian cancer. Methods Using the Multi-tumor markers Protein Chip Diagnose System to determine and analyze the concentration values of 12 tumor markers(AFP, CEA, NSE, CA125, CA153, CA242, CA199, PSA, f-PSA, FER, ?-HCG and HGH) in the sera of 53 malignant ovarian cancer patients, 12 ovarian cysts patients and 98 normal persons. Result At least one kind of tumor marker was found higher in 44 sera of the 53 malignant ovarian cancer patients(positive ratio is 83 0%), in 7 sera of the 12 ovarian cysts patients(positive ratio is 58 3%) and 2 sera of the 98 normal persons (negative ratio is 97 9%). NSE、HGH、PSA and f-PSA were first found higher in the sera of ovarian cancer patients. Conclusion The application of Multi-tumor markers Protein Chip Diagnose System in the diagnosing of cancer not only greatly reduces analysis of tumor markers concentration in serum and left the accuracy of diagnosis but may lead new discoveries about the tumor markers.